A PUBLIC health advocacy group has helped blow the lid off a brazen heist— the attempt by a US drug company to corner the intellectual property rights (IPRS) on a covid-19 vaccine it developed in collaboration with the government. The company is Moderna, the darling of both Wall Street because of its ability to garner huge funds, and of public health campaigners because of its promise of sharing its technology. But corporate greed has seen the unraveling of a model partnership that would bring new drugs quickly to the market and ensure fair pricing.
It is an egregious appropriation because the vaccine is the result of a four-year collaboration between Moderna and the US National Institutes of Health (NIH); the government described it as the NIH-Moderna covid-19 vaccine in its documents. Although the company had not brought a single product into the market previously, the government had poured billions into the research project, which accelerated after the pandemic struck. Most estimates have put the funding it received from various government agencies at the US $2.5 billion, but a recent New York Times (NYT) report says Moderna has received nearly $10 billion in taxpayer funding “to develop the vaccine, test it and provide doses to the federal government”.
The dream of a people’s vaccine, as it was dubbed last year by public health campaigners, is fading fast as the controversy over who should be credited with developing the vaccine heads for the courts. That is because the government is finally saying enough is enough and is contesting Moderna’s claims of having developed the vaccine on its own. NIH is, in a surprising and heartening turn, insisting that its scientists who developed the technology be credited in the patent application made by the company.
ãã®èšäºã¯ Down To Earth ã® December 01, 2021 çã«æ²èŒãããŠããŸãã
7 æ¥éã® Magzter GOLD ç¡æãã©ã€ã¢ã«ãéå§ããŠãäœåãã®å³éžããããã¬ãã¢ã ã¹ããŒãªãŒã9,000 以äžã®éèªãæ°èã«ã¢ã¯ã»ã¹ããŠãã ããã
ãã§ã«è³Œèªè ã§ã ?  ãµã€ã³ã€ã³
ãã®èšäºã¯ Down To Earth ã® December 01, 2021 çã«æ²èŒãããŠããŸãã
7 æ¥éã® Magzter GOLD ç¡æãã©ã€ã¢ã«ãéå§ããŠãäœåãã®å³éžããããã¬ãã¢ã ã¹ããŒãªãŒã9,000 以äžã®éèªãæ°èã«ã¢ã¯ã»ã¹ããŠãã ããã
ãã§ã«è³Œèªè ã§ã? ãµã€ã³ã€ã³
Trade On Emissions
EU's Carbon Border Adjustment Mechanism, a tariff on imports, is designed to protect European industries in the guise of climate action.
'The project will facilitate physical and cultural decimation of indigenous people'
The Great Nicobar Project has all the hallmarks of a disaster-seismic, ecological, human. Why did it get the go-ahead?
TASTE IT RED
Popularity of Karnataka's red jackfruit shows how biodiversity can be conserved by ensuring that communities benefit from it
MANY MYTHS OF CHIPKO
Misconceptions about the Chipko movement have overshadowed its true objectives.
The politics and economics of mpox
Africa's mpox epidemic stems from delayed responses, neglect of its health risks and the stark vaccine apartheid
Emerging risks
Even as the world gets set to eliminate substances threatening the ozone layer, climate change and space advancement pose new challenges.
JOINING THE CARBON CLUB
India's carbon market will soon be a reality, but will it fulfil its aim of reducing emissions? A report by PARTH KUMAR and MANAS AGRAWAL
Turn a new leaf
Scientists join hands to predict climate future of India's tropical forests
Festering troubles
The Democratic Republic of Congo struggles to contain mpox amid vaccine delays, conflict and fragile healthcare.
India sees unusual monsoon patterns
THE 2024 southwest monsoon has, between June 1 and September 1, led to excess rainfall in western and southern states such as Gujarat, Maharashtra and Tamil Nadu, while others like Nagaland, Manipur and Punjab recorded a deficit.